Postmarket Study Published on Elixir Medical's DESolve Bioresorbable Scaffold
November 27, 2018—Twelve-month results from the multicenter postmarket clinical follow-up study of the DESolve novolimus‐eluting bioresorbable coronary scaffold system (Elixir Medical Corporation) were published by Holger Nef, MD, et al in Catheterization and Cardiovascular Interventions (2018;92:1021–1027). The investigators concluded that the DESolve bioresorbable scaffold (BRS) is a safe and effective treatment for coronary lesions in patients with stable coronary artery disease.
According to the investigators, the DESolve BRS combines a poly‐L‐lactide–based backbone with a biodegradable polylactide‐based polymer and novolimus, a macrocyclic lactone mTOR inhibitor.
The study enrolled 102 patients (mean age, 62 years; 77.5% men) at 10 European sites. Investigators performed a comparison of baseline and postprocedural angiographic assessments. Additionally, they examined a device‐oriented composite endpoint (cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization) and rate of scaffold thrombosis at 12 months.
As reported in Catheterization and Cardiovascular Interventions, the device was successfully delivered and deployed in 98.2% (107/109) of the lesions, with two failures to cross the lesion. A total of 100 patients (109 lesions) were treated with the DESolve BRS. Postprocedural angiographic assessment indicated an in‐scaffold acute gain of 1.54 ± 0.44 mm, with a reduction in percent diameter stenosis from 61.00% ± 11.29% to 12.69% ± 0.44%.
At 12 months, the device‐oriented composite endpoint had occurred in 3% (3/100) of patients, with 1% (1/100) experiencing scaffold thrombosis and myocardial infarction and 3% (3/100) undergoing target lesion revascularization. There were no cardiac deaths.
Larger long‐term prospective studies are needed, advised the investigators in Catheterization and Cardiovascular Interventions.
advertisement
Featured Video
Patients have to trust that if I were in their shoes, I wouldn’t do anything differently.
Sponsored by Boston Scientific
Related Articles
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Top 5 Articles From October 2018
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
By Ginger Biesbrock, PA-C, MPH, MPAS, AACC; and Joel Sauer, MBA
Planning for Transcatheter Aortic Valve Replacement
By Moderator: Mauricio G. Cohen, MD, FACC, FSCAI
Panel: Santiago Garcia, MD, FACC, FSCAI; William O’Neill, MD; and Molly Szerlip, MD, FACC, FSCAI
Top 5 from EVToday's Current Issue
Novel Mechanical Thrombectomy Tools for Venous Thromboembolism
Dr. Antonious Attallah and Dr. Herman Kado report on recent FlowTriever and ClotTriever PE and DVT cases, and extracted clot images are presented from recent procedures performed across the United States.
With Antonious Attallah, MD, FACC, FSCAI; and Herman Kado, MD, FACC, FSCAI, RPVI
Training for Proficiency in Transradial Access for Lower Extremity Interventions
A stepwise approach to utilizing transradial access for iliac and femoropopliteal interventions.
By Andrew M. T. L. Choong, MBBS, FRCS (Gen Surg), FEBVS (Hons), MFSTEd, FAMS (Gen Surg); Ian J. Y. Wee; Nicholas L. Syn; and Stanley E. K. Loh, MBChB, MRCS, FRCR
Predictions for Transradial Access Capabilities in the Near Future
A discussion of available technology for transradial access in patients with aortoiliac and infrainguinal disease, current limitations, and opportunities for the future.
By Young Joon (Fred) Kwon, MSE; Raghuram Posham, MD, MPA; Rahul S. Patel, MD, FSIR; and Aaron Fischman, MD, FSIR, FCIRSE
Treatment Paradigms for Type B Aortic Dissection–Related Malperfusion and Rupture
Assessing the pathophysiology and endovascular treatments for complicated type B aortic dissection with malperfusion or rupture.
By Grace J. Wang, MD, MSCE, FACS
Optimal Room Setup for Transradial Access
Tips for patient and equipment positioning to allow safe, successful, and efficient TRA-based interventions.
